CCL5 and stage 5 chronic kidney disease: Only Böger et al. [10], who investigated RANTES promoter and intronic polymorphisms in type 2 diabetes/end stage renal disease, reported that patients carrying the RANTES-403A or In1.1C allele had higher all-cause mortality risk, mainly due to cardiac events.